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Summary  27 
Duchenne Muscular Dystrophy arises from the loss of dystrophin and is characterised by 28 
Ca2+ dysregulation, muscular atrophy and metabolic dysfunction. The secondary reduction of 29 
neuronal nitric oxide synthase (nNOS) from the sarcolemma reduces NO production and 30 
bioavailability. As NO modulates glucose uptake, metabolism and mitochondrial 31 
bioenergetics, we investigated whether an 8 week nitrate supplementation regimen could 32 
overcome metabolic dysfunction in the mdx mouse. Dystrophin-positive control (C57BL/10) 33 
and dystrophin-deficient mdx mice were supplemented with sodium nitrate (85mg.L-1) in 34 
drinking water. Following the supplementation period, extensor digitorum longus and soleus 35 
were excised and radioactive GU was measured at rest (basal) and during contraction. 36 
Gastrocnemius was excised and mitochondrial respiration was measured using the 37 
Oroboros Oxygraph. Tibialis anterior was immunohistochemically analysed for the presence 38 
of dystrophin, nNOS and nitrotyrosine and histologically analysed to assess areas of 39 
damage and regeneration. Basal and contraction-induced glucose uptake was lower in 40 
dystrophic muscle and could not be rescued with nitrate supplementation. The mitochondrial 41 
utilisation of substrates was also impaired in mdx gastrocnemius during phosphorylating and 42 
maximal uncoupled respiration and nitrate could not improve respiration in mdx muscle. 43 
Although nitrate supplementation reduced mitochondrial hydrogen peroxide emission, it 44 
induced mitochondrial uncoupling in red gastrocnemius, increased muscle fibre peroxynitrite 45 
(nitrotyrosine) and promoted skeletal muscle damage. Our novel data suggests that despite 46 
lower nNOS protein expression and likely lower NO production in mdx muscle, enhancing 47 
NO production with nitrate supplementation in these mice has detrimental effects on skeletal 48 
muscle. This may have important relevance for those with DMD. 49 
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Duchenne Muscular Dystrophy (DMD) is a progressive X-linked [1] neuromuscular 55 
disease affecting 1 in 3,500-5,000 live male births [2], which arises from the ablation of the 56 
cytoskeletal protein, dystrophin [3]. Dystrophin deficiency causes alterations to the myofibre 57 
architecture leading to membrane lesions, calcium (Ca2+) accumulation, muscular weakness 58 
and cyclic bouts of degeneration and regeneration until the regenerative capacity of the 59 
muscle is unable to match demand for repair [4]. Damaged muscle is eventually replaced 60 
with fibrous and/or fatty connective tissue leading to a decrease in muscle function, with 61 
cardiorespiratory failure ensuing by the third decade of life [5].   62 
Mitochondrial and metabolic dysfunction have been increasing implicated in the 63 
pathogenesis of DMD although it is not known if these abnormalities are associated with 64 
dystrophin deficiency, the pathophysiological sequelae caused by dystrophin deficiency, or 65 
completely independent of dystrophin deficiency [6]. Indeed, the only obvious physical link 66 
between dystrophin and the intracellular metabolic pathways is via neuronal nitric oxide 67 
synthase (nNOS) whereby ablation of dystrophin from the sarcolemma induces the 68 
secondary loss of the dystrophin-associated proteins [7] including nNOS [8, 9]. nNOS 69 
produces NO, a key signalling molecule in skeletal muscle that regulates various biological 70 
processes including blood flow, contraction, mass, satellite cell activation, Ca2+ handling and 71 
glucose uptake (GU), in addition to mitochondrial metabolism, gene expression and reactive 72 
oxygen species (ROS) production [10]. In dystrophic muscle, the dissociation of nNOS from 73 
the sarcolemma results in reduced nNOS content [11, 12, 13, 14], activity [9, 15, 16] and NO 74 
production [17, 18, 19]. Importantly, this loss of nNOS has been shown to contribute to the 75 
progression of the dystrophic condition and to the deficits in metabolic function. For example, 76 
nNOS is a positive allosteric regulator of phosphofructokinase (PFK), the rate limiting 77 
enzyme of the glycolytic pathway [20], and therefore plays a critical role in regulating glucose 78 
metabolism. Interestingly, DMD is not only associated with impairments in glycolysis [20, 21, 79 
22] but also in β-fatty acid oxidation, the tricarboxylic acid cycle (TCA) and the electron 80 
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transport system (ETS) (for detailed reviewed see [6]). Collectively, these metabolic 81 
impairments result in reduced energy production [23], with reports of ATP content being 50% 82 
lower under resting conditions [24, 25]. Given that nNOS localisation and NO signalling are 83 
known to be important for metabolic control, the loss of nNOS and NO bioavailability might 84 
be key to metabolic deregulation in dystrophic skeletal muscle. Therefore, increasing NO 85 
availability has the potential to be of therapeutic benefit. 86 
In an attempt to normalise NO production, several studies have reintroduced nNOS 87 
into dystrophic skeletal muscle which demonstrably reduces muscle damage and 88 
inflammation [26, 27]. As gene therapy for nNOS transfection is not yet available in humans, 89 
other strategies to restore NO availability have been investigated. Several studies have 90 
shown that supplementation with NO donors, often combined with anti-inflammatory drugs, 91 
results in reduced damage, necrosis and inflammation and improved muscle blood flow, 92 
function/strength and repair [28, 29, 30, 31, 32, 33, 34, 35] in dystrophin-deficient skeletal 93 
muscle. While these findings may suggest a positive effect of increasing NO availability, it is 94 
difficult to control the delivery of NO to the skeletal muscle with pharmacological donors and 95 
also to separate the effects of the NO donor from those of the anti-inflammatory co-96 
treatment. Another approach to increase NO availability has been to supplement with the 97 
nNOS substrate, ʟ-arginine [19]; however, the potential for ˪-arginine to increase NO 98 
production is limited by the lowered nNOS protein in dystrophic skeletal muscle. An 99 
alternative method to increase NO availability, that is independent of nNOS activity, is 100 
supplementation with nitrate (NITR). Specifically, dietary NITR can be reduced to nitrite by 101 
commensal bacteria of the oral cavity and gastrointestinal tract, with nitrite being 102 
subsequently reduced to NO via several enzymatic pathways in the blood and tissues [36]. 103 
This mechanism is complementary to NOS-derived NO production and, importantly, 104 
represents a pathway that could be exploited to increase NO availability in dystrophic 105 
muscle.  106 
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To date, no studies have investigated the effect of NITR supplementation on 107 
metabolic function in dystrophic muscle; however, recent studies suggest that NITR 108 
supplementation has the potential to improve metabolic function in skeletal muscle. For 109 
example, Larsen et al. [37] demonstrated that NITR supplementation in healthy, young 110 
males led to increased plasma NO concentration and subsequently, downstream metabolic 111 
adaptations including increased mitochondrial efficiency, reduced proton leak and ultimately  112 
increased ATP production capacity. Similar data has been derived in rats during fatty acid 113 
oxidation [38]. In addition, there is some evidence that NITR supplementation can increase 114 
exercise efficiency in humans [39, 40, 41] and exercise capacity in some disease conditions 115 
such as peripheral arterial disease, where NO production is reduced [42]. Most pertinently, 116 
increasing NO bioavailability through administration of sodium nitrite mitigates functional 117 
ischemia in Becker Muscular Dystrophy patients [43] suggesting that expansion of the NITR-118 
nitrite-NO pool in DMD may also be beneficial. The results from these studies prompted us 119 
to investigate whether increasing NO availability via NITR supplementation, which has been 120 
previously proven to increase plasma [37, 44] and skeletal muscle [38] NO levels and elicit 121 
beneficial mitochondrial adaptations at the skeletal muscle level [37, 44], would improve 122 
mitochondrial function and rectify energy homeostasis dysregulation in dystrophic muscle. 123 
Therefore, we investigated whether an established dietary NITR supplementation regimen 124 
[44] could improve GU, mitochondrial function, ROS emission and muscle architecture in 125 
healthy (control; CON) and dystrophic (mdx) mouse models. We hypothesised that NITR 126 
supplementation would (1) increase GU in the contracting muscles from CON and mdx mice; 127 
(2) improve mitochondrial function in mdx mice and; (3) improve the muscle architecture of 128 







Materials and Methods 134 
Ethical approval  135 
All experimental procedures were approved by the Victoria University Animal Ethics 136 
Experimentation Committee and conformed to the Australian Code of Practice for the Care 137 
and Use of Animals for Scientific Purposes.  138 
Animals and supplementation  139 
Three week-old male C57Bl/10ScSn (normal wild-type strain; CON) and 140 
C57Bl/10mdx (mdx) mice were purchased from Animal Resources Centre (Western 141 
Australia, Australia) and housed at the Western Centre for Health, Research and Education 142 
(Sunshine Hospital, Victoria, Australia) on a 12:12 hour light-dark cycle with ad libitum 143 
access to food and water. Following a one week acclimatisation period, mice were randomly 144 
assigned into four groups: unsupplemented (CON UNSUPP and mdx UNSUPP) and 145 
supplemented (CON NITR and mdx NITR). Mice in the supplemented groups were given 85 146 
mg.L-1 (1mM) sodium NITR [44] ad libitum in drinking water for 8 weeks and mice in the 147 
unsupplemented groups were given drinking water without NITR. The dose of NITR is 148 
comparable to doses studied in human experiments, is achievable through a normal diet 149 
[45], and is proven to increase the plasma NITR-nitrite-NO pool [37, 44].  150 
Materials and antibodies 151 
All chemicals, unless stated otherwise, were purchased from Sigma-Aldrich 152 
Chemicals (St. Louis, MO). 2-Deoxy-ᴅ-[1,2-3H]glucose and ᴅ-[14H]mannitol were purchased 153 
from Perkin Elmer (Waltham, MA, USA). Dystrophin (ab15277), nNOS (ab1376), 154 
nitrotyrosine (ab42789) and Total OXPHOS (ab110413) primary antibodies were purchased 155 
from Abcam (MA, USA). Secondary antibodies for immunohistochemistry were purchased 156 
from Jackson Immunoresearch Laboratories (PA, USA) and for western blotting from Vector 157 
Laboratories (Burlingame, CA, USA). 158 
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Muscle dissection and contraction protocol  159 
Mice were deeply anaesthetised via intraperitoneal injection of sodium 160 
pentobarbitone (60mg/kg) and the white extensor digitorum longus (EDL) and red soleus 161 
(SOL) muscle proximal and distal tendons in each hind limb were tied with 4/0 surgical silk. 162 
Both EDL and SOL were surgically dissected tendon-to-tendon and placed into individual 163 
muscle baths containing Krebs basal buffer (118.5mM NaCl, 24.7mM NaHCO3, 4.74mM 164 
KCl, 1.18mM MgSO4, 2.5mM CaCl2, 8mM mannitol, 2mM Na pyruvate, 0.01% BSA; pH 7.4) 165 
bubbled with carbogen (95% O2, 5% CO2) at 30°C. The proximal tendon was attached to a 166 
force transducer and muscles were rested for 20 minutes to equilibrate in the bath. Muscles 167 
were stimulated via square wave electrical pulses delivered by platinum electrodes flanking 168 
the muscles, and subsequent recording of the force output were obtained from a custom-169 
built muscle analysis system (Zultek Engineering, Victoria, Australia). Following 170 
determination of optimal length (Lo) for each muscle via a succession of isometric twitch 171 
contractions, the left EDL and SOL were stimulated to contract for a total of 10 minutes 172 
(pulse durations of 350msec and 500msec for EDL and SOL, respectively at a frequency of 173 
60 Hz). This protocol maintains muscle viability and maximises GU [46]. The right EDL and 174 
SOL were not stimulated in order to measure basal GU.  175 
Glucose uptake 176 
Following 5 minutes of contraction, the Krebs basal buffer was exchanged for Krebs 177 
buffer with 2-Deoxy-ᴅ-[1,2-3H]glucose (0.128µCi/mL) and ᴅ-[14H]mannitol (0.083µCi/mL) in 178 
both resting and contracting muscles. At the end of the 10 minute contraction protocol, 179 
muscles were immediately submerged in ice-cold Krebs basal buffer to stop further glucose 180 
uptake, blotted on filter paper and snap frozen in liquid nitrogen. Whole muscles were 181 
weighed frozen, digested for 10 minutes at 95°C in 135µL of 1M NaOH, neutralised with 182 
135µL of 1M HCl and centrifuged for 5 minutes at 13,000g. 200µL of supernatant was added 183 
to 4mL of inorganic scintillation fluid (UltimaGold, Perkin Elmer) and radioactivity was 184 
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measured in a β-scintillation counter (Tri-Carb 2810, Perkin Elmer). GU was calculated [47] 185 
and corrected for sPo as described previously [48].  186 
Mitochondrial respiration and hydrogen peroxide emission measurements  187 
Left and right gastrocnemius were excised from the anaesthetised mice, separated 188 
into RG and WG portions and immediately placed into ice-cold BIOPS (7.23mM K2EGTA, 189 
2.77mM CaK2EGTA, 5.77mM Na2ATP, 6.56mM MgCl2-6H2O, 20mM taurine, 15mM 190 
phosphocreatine, 20mM imidizole, 0.5mM dithiothreitol, 50mM K+-MES; pH 7.1). Muscle 191 
fibres were mechanically separated from a small portion of muscle in ice-cold BIOPS to 192 
maximise fibre surface area and transferred into ice-cold BIOPS supplemented with saponin 193 
(50µg/mL) for 30 minutes. Separated fibres were agitated to permeabilise the sarcolemma 194 
and allow diffusion of subsequent assay substrates, and then washed three times via 195 
agitation in ice-cold respiration buffer (110mM K+-MES, 35mM KCl, 1mM EGTA, 5mM 196 
K2HPO4, 3mM MgCl2-6H2O, 0.05mM pyruvate, 0.02mM malate, 5 mg/mL BSA; pH 7.4). 197 
Fibre bundles were then divided and weighed on a microbalance (2-4 mg each) for 198 
subsequent respirometry analysis in duplicate.  199 
ETS respiration, OXPHOS and H2O2 emission were measured by the Oxygraph O2k 200 
high resolution respirometer (Oroboros Instruments, Innsbruck, Austria) via a substrate, 201 
uncoupler, inhibitor titration (SUIT) protocol at 37°C in MIR05 respiration medium while 202 
stirring at 750 rpm as previously described [49, 50], with minor modifications in order to 203 
assess H2O2 emission. Briefly, after fibres and oxygen (O2) were added to the respiration 204 
chamber, the SUIT protocol commenced with titrations of the complex I (CI) substrates 205 
malate (2mM final concentration) and pyruvate (10mM), followed by the complex II (CII) 206 
substrate succinate (10mM) to determine leak (state 4) respiration. Titrations of ADP (0.25, 1 207 
and 5mM) assessed OXPHOS (state 3) capacity, addition of cytochrome c (10µM) tested 208 
mitochondrial membrane integrity and titrations of FCCP (0.025µM) determined uncoupled 209 
respiration. Complex-specific respiration was inhibited by the addition of rotenone (1µM) and 210 
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antimycin A (5µM) to CI and complex III (CIII), respectively. Finally, complex IV (CIV) 211 
capacity was measured during oxidation of TMPD (0.5mM) with ascorbate (2mM). The O2 212 
flux due to autoxidation of these chemicals was determined after inhibition of CIV with 213 
sodium azide (75 mM) then subtracted from the raw CIV O2 flux.  214 
Mitochondrial H2O2 emission was simultaneously measured in the respiration 215 
chamber throughout the SUIT protocol via optical sensors (O2k-Fluorescence LED-2 216 
Module, Oroboros, Austria) as previously described [51, 52, 53]. Superoxide (O2-) produced 217 
during the SUIT protocol was converted to H2O2 due to the presence of a saturating 218 
concentration of O2- dismutase (2.5 U.mL-1), and the subsequent H2O2 generation was 219 
quantified via the reaction of Amplex UltraRed (25 µM; Molecular Probes, Invitrogen) with 220 
horseradish peroxidase (2.5 U.mL-1) at excitation/emission 565/600  nm wavelength. The 221 
H2O2 detection chemicals were added to the chambers containing MIR05 respiration 222 
medium at the beginning of the experiment, prior to the addition of the muscle fibres.  223 
Chamber O2 concentration was maintained between 300-450 nmol.ml-1. Mass 224 
specific O2 flux and H2O2 emission was determined from steady-state flux normalised to 225 
tissue wet weight and adjusted for instrumental background and residual O2consumption. 226 
Respiratory control ratios were calculated (complex specific O2 flux relative to maximal 227 
uncoupled ETS respiration) to investigate intrinsic mitochondrial function independent of 228 
mitochondrial density.  229 
Western blot analysis of mitochondrial respiratory chain proteins 230 
 Frozen tissues were homogenised for 20 seconds in ice-cold WB buffer (40 mM Tris, 231 
pH 7.5; 1 mM EDTA; 5 mM EGTA; 0.5% Triton X-100; 25 mM β-glycerophosphate; 25 mM 232 
NaF; 1 mM Na3VO4; 10 μg/ml leupeptin; and 1 mM PMSF), and the whole homogenate was 233 
used for further analysis. Sample protein concentrations were determined with a DC protein 234 
assay kit (Bio-Rad Laboratories, Hercules, CA, USA), and equivalent amounts of protein 235 
(15μg) from each sample were dissolved in Laemmli buffer, heated for 5 min at 37oC and 236 
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subjected to electrophoretic separation on SDS-PAGE acrylamide gels. Following 237 
electrophoretic separation, proteins were transferred to a PVDF membrane, blocked with 5% 238 
powdered milk in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h followed by 239 
an overnight incubation at 4°C with primary antibody dissolved in TBST containing 1% 240 
bovine serum albumin (BSA). The Total OXPHOS Antibody Cocktail (1:1000), which detects 241 
representative proteins from each of the five mitochondrial respiratory chain complexes, was 242 
obtained from Abcam. This cocktail consisted of primary antibodies against the following 243 
proteins: NADH Dehydrogenase (Ubiquinone) 1 Beta Sub-complex, 8 (NDUFB8; CI), 244 
Succinate Dehydrogenase Assembly Factor 4 (SDH8; CII), Ubiquinol-Cytochrome-C 245 
Reductase Complex Core Protein 2 (UQCRC2; Complex III; CIII), Mitochondrially Encoded 246 
Cytochrome C Oxidase I (MTOC1; Complex IV; CIV) and Mitochondrial ATP Synthase 247 
Subunit Alpha (ATPSA; Complex V; CV). After overnight incubation, the membranes were 248 
washed for 30 min in TBST and then probed with a peroxidase-conjugated secondary 249 
antibody (1:10000, anti-mouse, Vector Labs) for 1 h at room temperature. Following 30 min 250 
of washing in TBST, the blots were developed with a DARQ CCD camera mounted to a 251 
Fusion FX imaging system (Vilber Lourmat, Germany) using ECL Prime reagent 252 
(Amersham, Piscataway, NJ, USA). Once the images were captured, the membranes were 253 
stained with Coomassie Blue to verify equal loading of total protein in all lanes. 254 
Densitometric measurements were carried out using Fusion CAPT Advance software (Vilber 255 
Lourmat, Germany). 256 
Citrate Synthase Activity  257 
Homogenised RG and WG samples were utilised to measure citrate synthase (CS) 258 
activity as a marker of mitochondrial density [54, 55]. Homogenised samples were added to 259 
reagent cocktail (100 mM Tris Buffer, 1 mM DTNB, 3 mM Acetyl CoA) and CS activity was 260 
measured spectrophotometrically (412nm at 25°C) for 5 minutes following the addition of 261 
10mM oxaloacetate as described previously [23]. CS activity was calculated using the 262 
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extinction coefficient of 13.6 [56]. CS activity was normalised to whole muscle protein 263 
concentration.  264 
  265 
Histological Analysis 266 
Following excision, the right TA was frozen in liquid nitrogen-cooled isopentane and 267 
optimal cutting temperature compound (Sakura Finetek). Embedded TA’s were cryo-268 
sectioned (10µm) at -20°C using a Leica (CM1950) cryostat and mounted onto glass slides 269 
(Menzel-Glaser). 270 
Dystrophin and nNOS Immunolabelling  271 
Slides were fixed using a Cytofix/Cytoperm Plus kit (BD Biosciences) for 5 minutes. 272 
After incubation with blocking serum (0.1M PBS, 0.1% triton, 10% FBS) for 1 hour at room 273 
temperature, sections were labelled with primary antibodies: rabbit anti-dystrophin (1:400) 274 
and goat anti-nNOS (1:200) overnight at room temperature. After washing three times with a 275 
0.1M PBS and 0.1% triton X solution, samples were incubated with secondary antibodies: 276 
donkey anti-rabbit Alexa 488 (1:200) and donkey anti-goat Alexa 594 (1:200) for 2 hours at 277 
room temperature. Tissues were washed three times with a 0.1M PBS and 0.1% triton X 278 
solution and mounted with fluorescent mounting medium (DAKO, Australia). Confocal 279 
microscopy was performed on an Eclipse Ti confocal laser scanning system (Nikon, Japan). 280 
Fluorophores were visualized using a 488 nm excitation filter for Alexa 488 or FITC and a 281 
559 nm excitation filter for Alexa 594 or Rhodamine Red. Z-series images were acquired at a 282 
nominal thickness of 0.5μm (512x512 pixels). The density of dystrophin and nNOS 283 
immunoreactivity in TA sections was measured from eight randomly captured images (total 284 
area size 2mm2) per animal at 20x magnification.  All images were captured under identical 285 
acquisition exposure time conditions and calibrated to standardised minimum baseline 286 
fluorescence. Images were converted from red, green, and blue (RGB) to grayscale 8 bit 287 
then to binary; changes in fluorescence from the baseline were measured using Image J 288 
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software (NIH, USA). The area of immunoreactivity was then expressed as a percentage of 289 
the total area examined. Quantitative analyses were conducted blindly. 290 
  Nitrotyrosine, CD45 and IgG Immunolabelling 291 
Slides were fixed with 4% formaldehyde for 30 minutes at room temperature. After 292 
incubation with blocking serum (0.1M PBS, 0.1% triton, 10% donkey serum) for 1 hour at 293 
room temperature, sections were then labelled with primary anti-S-nitrotyrosine (rabbit; 294 
1:200; Millipore), anti-CD45 (pan-leukocyte marker; rat; 1:200) and anti-IgG isotype control 295 
(hamster; 1:200) primary antibodies overnight at room temperature. After washing three 296 
times with a 0.1M PBS and 0.1% triton X solution, samples were incubated with the 297 
appropriate secondary antibody (anti-rabbit Alexa Fluor 647, 1:100, Abacus ALS, UK; anti-298 
rat Alexa Fluor 488, Jackson Immuno Research; anti-hamster Alexa Fluor 594, Jackson 299 
Immuno Research) for 2 hours at room temperature. A pan nuclei marker DAPI (4',6-300 
diamidino-2-phenylindole) was added to the tissue sections and incubated for 2 minutes at 301 
room temperature, tissues were washed three times with a 0.1M PBS and 0.1% triton X 302 
solution and mounted with an anti-fade fluorescent mounting medium. Excitation 303 
wavelengths were set to 640nm for Alexa 647,  406nm for Alexa 405, 408.8nm for Alexa 304 
Fluor 488 and 561.8nm for Alexa Fluor 594. The confocal microscope was calibrated to 305 
standardise the minimum baseline fluorescence for imaging nitrotyrosine, CD45 and IgG 306 
immunoreactivity in the TA cross sections. At time of analysis all files were converted to 307 
thresholded 8-bit binary images using ImageJ software from eight randomly captured images 308 
per animal. Images were analysed through the ‘analyze particles’ function, recording the 309 
counts (to determine the number of DAPI positive nuclei) and relative nitrotyrosine 310 
expression recorded as percentage area fraction in arbitrary units. Green pseudocolor 311 
images of nitrotyrosine (Alexa Fluor 647; magenta) were generated using ImageJ software 312 
for publication only.  313 
Haematoxylin & Eosin Staining 314 
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Slides were air-dried and stained using a haematoxylin and eosin (H&E) staining 315 
protocol including a 30 second incubation in haematoxylin and a 1 minute and 45 second 316 
incubation in eosin. Slides were imaged using a Zeiss Axio Imager Z2 microscope at 20x 317 
magnification. Fibre size, damaged area (areas of myofibril demise and inflammatory cell 318 
infiltration [57] and fibres with centralised nuclei were determined using ImageJ software.  319 
 320 
Statistics 321 
Results are presented as mean ± standard error of the mean. For all data, except for 322 
GU, a two-way ANOVA was utilised to detect between strain/genotype (CON vs. mdx) and 323 
supplementation (UNSUPP vs. NITR) differences.  For GU data, a three-way ANOVA was 324 
performed for each of EDL and SOL to detect between strain, supplementation and GU type 325 
(basal vs. contraction). When a main effect or an interaction was detected, unpaired T-tests 326 
were used to determine differences between individual groups using SPSS (version 21). An 327 




Results  332 
Effect of NITR supplementation on body weight, food and water consumption 333 
and muscle weights 334 
Throughout the 8 week supplementation period, greater weight gains were observed 335 
in the mdx groups compared to CON (p<0.0001; Figure 1A), with NITR having no effect in 336 
mdx mice (p>0.05). NITR did, however, stimulate weight gain in CON (p<0.05). No 337 
significant difference in food or water consumption was observed between any group over 338 
the supplementation period (Figure 1B & C respectively; p>0.05) except at week two where 339 
food consumption was greater in CON UNSUPP compared to all groups (p<0.05, Figure 340 
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1B). Overall, individual hind limb muscle weights were greater in the mdx compared to CON 341 
strain (p<0.0001; Table 1 and 2) with NITR having no effect (p>0.05).  342 
Immunolabelling of dystrophin and nNOS  343 
To confirm the deficiency of both dystrophin and nNOS in mdx skeletal muscle, the 344 
presence of dystrophin and nNOS protein (Figure S1) was determined in the TA. Indeed, 345 
dystrophin was only evident in CON TA (Figure S1A and C) and was absent from mdx TA 346 
except for a few spontaneously revertant fibres (p<0.0001). Similarly, nNOS was only 347 
evident in CON TA (Figure S1AI and CI) and was completely absent from dystrophin-348 
deficient mdx fibres (p<0.0001). Co-localisation of dystrophin and nNOS was only observed 349 
in CON (Figure S1AII and CII) and NITR had no effect on either dystrophin or nNOS 350 
expression (p>0.05).  351 
Effect of NITR supplementation on glucose uptake   352 
NO has been proposed to play a role in contraction-stimulated GU and as such, we 353 
first investigated the effect of NITR supplementation on GU in CON and mdx muscles. This 354 
is the first instance of contraction-induced GU being measured in the mdx mouse and we 355 
demonstrated no difference in basal- or contraction-induced GU between CON and mdx 356 
UNSUPP EDL (p>0.05, Figure 2A). As expected, contraction induced an increase in GU in 357 
the EDL’s of CON UNSUPP (55%), CON NITR (61%), mdx UNSUPP (35%) and mdx NITR 358 
(51%) compared to basal conditions (p<0.05, Figure 2A). NITR supplementation significantly 359 
increased contraction-induced GU in CON EDL muscles (p<0.05; Figure 2A) however in 360 
contrast,  NITR reduced both basal- and contraction-induced GU in mdx muscles (p<0.05; 361 
Figure 2A). Contrary to the EDL, contraction did not stimulate further GU beyond that 362 
observed in basal conditions for any group in the SOL (all less than 20%, p>0.05, Figure 363 
2B). While NITR had no effect on basal or contraction-induced GU in CON SOL muscles 364 
(p>0.05; Figure 2B), NITR further reduced both basal and contraction-induced GU in mdx 365 
SOL muscles (p<0.05).  Combined, these data suggest that NITR supplementation has a 366 
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negative effect on GU in both mdx EDL and SOL which may lead to impairments in 367 
downstream glycolysis and oxidative metabolism.   368 
Effect of NITR supplementation on mitochondrial function  369 
Respirometry 370 
Next, we examined the effect of NITR on parameters of mitochondrial function. First, 371 
we measured state 4 leak respiration which, in the absence of ADP, indicates the 372 
contribution of proton leak to respiration. In the presence of pyruvate and malate (CI), state 4 373 
leak respiration was significantly lower in mdx white (WG) (p<0.05; Figure 3A) and red 374 
gastrocnemius (RG) (p<0.01; Figure 3C) muscles compared to their respective controls. In 375 
the presence of pyruvate, malate and succinate (CI+II), state 4 leak respiration was 376 
significantly higher than CI respiration across all groups, in both WG and RG muscles 377 
(p<0.0001; Figure 3A and 3C, respectively). NITR supplementation had no effect on either 378 
CI or CI+II state 4 leak respiration in CON or mdx muscles (Figure 3A and 3C). 379 
Next, the effect of NITR on coupled OXPHOS capacity was examined in WG and RG 380 
muscles by assessing maximal ADP-stimulated state 3 respiration in the presence of excess 381 
malate, pyruvate and succinate (complex I and II (CI+II) substrates). As shown in Figure 3, 382 
state 3 respiration was significantly depressed in mdx WG by ~15% (p<0.05; Figure 3A) and 383 
in mdx RG by 25% (p<0.001; Figure 3C) compared to CON. NITR supplementation, 384 
however, had no effect on State 3 respiration in either muscle (Figure 3A and 3C).  385 
Maximal ETS capacity was then assessed by the addition of the uncoupling agent 386 
FCCP, which dissipates the mitochondrial membrane potential (ΔΨ). This parameter gives 387 
an indication of the maximal respiration in the uncoupled state. FCCP-induced maximal 388 
uncoupled respiration was significantly lower in mdx WG (p<0.05; Figure 3A) and RG 389 
(p<0.001; Figure 3C) compared to their respective controls; however, there was no effect of 390 
NITR on this parameter.   391 
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Next, we measured the activity of CIV (cytochrome C oxidase), the terminal oxidase 392 
of the   ETS and the site of O2 reduction to water. As shown in Figure 3, CIV activity was not 393 
different between UNSUPP CON and mdx WG muscles (Figure 3A); however, in the RG 394 
muscles, CIV activity was significantly lower in mdx UNSUPP compared to CON UNSUPP 395 
(p<0.01; Figure 3C). NITR induced a significant increase in CIV activity in CON WG muscles 396 
(p<0.01; Figure 3A) but reduced CIV activity in both CON and mdx RG muscles (p<0.01; 397 
Figure 3C).  398 
Finally, the respiratory control ratio (state 3 respiration divided by state 4 respiration; 399 
RCR) was calculated. The RCR is an indicator of the extent to which O2 consumption is 400 
coupled to ATP production and therefore mitochondrial efficiency, with a higher RCR 401 
indicating better coupling. No difference in RCR was observed between CON and mdx WG 402 
(p>0.05, Figure 5B). In mdx RG respiring on CI+II, the RCR was significantly lower 403 
compared to CON (p<0.0001) and NITR decreased the RCR further (p<0.01, Figure 3D). 404 
This highlights that in oxidative red muscle at least, mdx mitochondria are more uncoupled 405 
and that this uncoupling is exacerbated by NITR. 406 
Electron Transport Chain Complex Expression 407 
To determine whether the genotypic differences and NITR supplementation-induced 408 
changes in respiration parameters were associated with differences in mitochondrial ETS 409 
complex densities, the abundance of representative proteins from each of the five ETS 410 
complexes were measured using semi-quantitative Western blotting (Figure 4 and 5). In WG 411 
muscles, despite state 3, state 4 and maximal uncoupled respiration being lower in mdx 412 
muscles (Figure 3A), the relative abundance of representative proteins from complexes I to 413 
V were not lower. In fact, to the contrary, proteins from CII, CIII, CIV and CV were 414 
significantly elevated in mdx UNSUPP WG muscles compared to CON UNSUPP muscles 415 
(Figure 4). Interestingly, the NITR-induced increase in CIV respiratory activity (Figure 3A) 416 
was not associated with a significant increase in the abundance of the CIV protein (Figure 417 
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4D). NITR supplementation did, however, lead to an increase in representative proteins in 418 
WG muscles for CI, CII, CIII and CV in CON but not mdx muscles (Figure 4). 419 
Unlike the WG muscles, the lower state 3, state 4, uncoupled respiration and CIV 420 
activity found in RG mdx muscles (Figure 3C) was accompanied by a reduction in 421 
representative proteins for CI, CII, CIV and CV compared with CON; however, NITR 422 
supplementation had no effect on any of these proteins in either CON  or mdx RG muscles 423 
(Figure 5). 424 
Citrate Synthase Activity 425 
Finally, we measured citrate synthase (CS) activity in WG and RG muscles as a co-426 
marker of mitochondrial content alongside mitochondrial ETC proteins [58] (Figure 4F and 427 
5F, respectively). As shown in Figure 4F, there was a trend for CS activity to be higher in 428 
mdx UNSUPP compared to CON UNSUPP WG muscles. Moreover, NITR increased CS 429 
activity in both CON and mdx WG muscles. In the RG muscles there was no difference in 430 
CS activity between UNSUPP CON and mdx mice; however, NITR increased CS activity in 431 
RG muscles from mdx mice. Overall, NITR did not improve the capacity to phosphorylate 432 
ATP or maximal respiratory capacity in dystrophic muscle despite increasing CS activity, 433 
suggesting that NITR may have an alternative effect on mitochondrial function such as ROS 434 
generation.  435 
Effect of NITR supplementation on ROS production in red and white 436 
gastrocnemius  437 
The effect of NITR supplementation on the production of the mitochondrial ROS 438 
superoxide (O2-), was measured in intact and permeabilised fibres from WG and RG 439 
simultaneously with respiration. In the presence of excess O2- dismutase, O2- is converted to 440 
hydrogen peroxide (H2O2), which reacts with Amplex Red to produce the red fluorescent 441 
product, resorufin. During state 3 respiration, no differences in H2O2 emission was detected 442 
between  CON and mdx UNSUPP WG (p>0.0 5; Figure 6A) with NITR having no effect in 443 
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either strain (p>0.05; Figure 6A). NITR did, however, induce a decrease in H2O2 emission 444 
during state 4 leak respiration in CON WG muscle fibres respiring on CI substrates (p<0.05; 445 
Figure 6A). When respiring on CI+CII substrates, there was significantly greater H2O2 446 
emission in all groups during state 4 leak respiration compared to CI substrates only in WG 447 
fibres (p<0.0001; Figure 6A). Importantly, NITR significantly decreased H2O2 emission in 448 
both CON and mdx WG muscles respiring during state-4 while on CI+II substrates (p<0.05; 449 
Figure 6A). There was no difference in H2O2 emission in WG between any groups during 450 
FCCP-stimulated maximal uncoupled respiration (p>0.05; Figure 6A).  451 
In mdx RG fibres, there was significantly less H2O2 emission during state 3 452 
respiration (p<0.05; Figure 6B) compared to CON fibres; however, there was no effect of 453 
NITR on this parameter (p>0.05). Similar to WG fibres, H2O2 emission was higher when 454 
respiring on CI+CII substrates compared to CI substrates across all groups during state 4 455 
leak respiration (p<0.0001), however, NITR only reduced H2O2 emission in mdx fibres 456 
(p<0.001; Figure 6B). NITR also reduced H2O2 emission in mdx RG fibres during FCCP 457 
uncoupled respiration (p<0.05; Figure 6B). While our data suggests that NITR reduces 458 
mitochondrial ROS production in dystrophic muscle, it is possible that increased NO 459 
bioavailability may sequester O2- from the O2- dismutase reaction to increase reactive 460 
nitrogen species (RNS).  461 
Effect of NITR supplementation on peroxynitrite production, CD45-positive(+) 462 
infiltration and IgG immunolabelling  463 
NO is known to rapidly react with O2- resulting in the production of the highly RNS, 464 
peroxynitrite (ONOO-), and given that elevated ROS is present in mdx muscle [59], we 465 
investigated whether ONOO- production could account for the reduced H2O2 emission 466 
observed in our study. Increased ONOO- can result in increased protein nitration of tyrosine 467 
residues, potentially leading to altered protein function. Therefore, as an indirect marker of 468 
oxidative/nitrosative stress, we measured the effect of NITR on levels of nitrotyrosine via 469 
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immunohistochemical staining of TA muscles. Mdx muscles had significantly higher 470 
nitrotyrosine staining compared to CON muscles (p<0.0001) and NITR increased 471 
nitrotyrosine staining in both CON (p<0.05) and mdx (p<0.0001) TA (Figure 7A).  472 
Importantly, NITR inducing a dramatically greater increase in nitrotyrosine production in mdx 473 
muscles (2775% increase compared to 82% increase in CON). Additionally, NITR further 474 
increased the presence of DAPI-stained nuclei in NITR supplemented mdx TA (p<0.0001, 475 
Figure 7B) . To assess if the increased nitrotyrosine staining was associated with increased 476 
inflammation, we measured CD45+ immune cell infiltration and IgG via immunolabelling. In 477 
mdx TA, both CD45+ and IgG+ area was elevated compared to CON muscles (p<0.001 and 478 
p<0.01 respectively, Figure 7C and D respectively). In contrast to nitrotyrosine staining, 479 
NITR had no effect on the CD45+ and IgG+ area  in either strain (p>0.05).  480 
Effect of NITR supplementation on muscle architecture  481 
Finally, we assessed the effect of NITR on muscle fibre histopathology. As expected, 482 
intact mdx muscle fibres were significantly larger than fibres from CON muscles (Figures 8A 483 
and C) which is representative of pseudohypertrophy, a hallmark histopathological feature of 484 
dystrophin-deficient muscle. Interestingly, there was a strong trend for NITR 485 
supplementation to increase the number of fibres between 6000 and 7499 μm2 (p=0.068; 486 
Figure 8A) and increase total mean fibre size (p=0.093; Figure 8C). The area of damage, as 487 
indicated by areas of inflammatory cell/nuclei infiltration, was significantly higher in mdx 488 
(p<0.01; Figure 8D) compared to CON TA sections and NITR significantly increased the 489 
damage area in mdx muscle (p<0.01). Centronucleated fibres, a marker of muscle cell 490 
regeneration, were significantly higher in mdx muscle (p<0.0001; Figure 8E) with NITR 491 
further increasing regeneration area in mdx sections (p<0.01). These results show that NITR 492 
supplementation enhances muscle damage, but also regeneration, in mdx TA but not in 493 





This is the first study to date to investigate NITR supplementation as a potential 497 
therapy for DMD and we show that the metabolic perturbations in dystrophin-deficient 498 
skeletal muscle could not be overcome by enhancing nNOS-independent NO production. 499 
Instead, our data suggests that chronically increasing NO bioavailability without restoring 500 
nNOS protein expression and its regulatory role on metabolism, in fact, promotes 501 
pathological muscle damage, potentially via a peroxynitrite (ONOO-)-dependent mechanism. 502 
In the first instance we investigated if impaired macronutrient uptake may be a 503 
contributing factor to the mitochondrial dysfunction in dystrophic muscle, as compromised 504 
transport of substrates across the sarcolemma could be a consequence of the loss of 505 
dystrophin and nNOS from the membrane. Specifically, we have investigated glucose uptake 506 
(GU) as it is well established that GU during rest and contraction is regulated by NO [46]. 507 
The secondary loss of dystrophin-associated nNOS was confirmed in mdx TA via 508 
immunolabelling. Concurrently, we have demonstrated that both basal- and contraction-509 
induced GU  in both mdx UNSUPP EDL and SOL is comparable to CON.  We have 510 
demonstrated in our study that NITR increases contraction-induced GU in CON EDL but has 511 
no effect in CON SOL. Indeed, we have shown previously that there are greater effects of 512 
NOS inhibition on EDL than SOL [46], likely because of a greater comparative nNOS 513 
expression in fast-twitch versus slow-twitch muscles [46, 60] and  the higher antioxidant 514 
enzymes in slow-twitch muscles which may buffer the effects of NO [61]. In both CON EDL 515 
and SOL muscles, however, NITR did not affect basal GU rate. This could infer that the 516 
NITR dosage administered in our study is sufficient to modulate non-cGMP-dependent 517 
contraction-induced GLUT-4 mediated GU [62] but perhaps not cGMP-dependent GLUT-1 518 
basal [63]  events. A notable limitation of our study is that we did not quantify cGMP levels in 519 
EDL and SOL muscles. However, in light of a recent study which demonstrated that even 520 
low dose (0.35mM) NITR therapy  for ~2 weeks (in comparison to the 1mM NITR dosage for 521 
8 weeks administered in our study) was sufficient to induce ~3-fold increases in cGMP levels 522 
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in rat skeletal muscle, this seems unlikely. Rather, basal GU is likely regulated in the first 523 
instance by glucose utilisation, thus increasing NO signalling without the normal 524 
simultaneous increase in muscle work (and thus glucose utilisation) results in an unchanged 525 
basal GU. Unexpectedly and in contrast to CON EDL, NITR reduced basal GU in mdx EDL 526 
and SOL. Taken with the fact that NITR stimulated contraction-induced GU in CON but 527 
further depressed it in mdx muscle, our data suggests that NITR-derived NO is being 528 
diverted away from its bio-modulatory effects on GU. Presumably, this is because in mdx 529 
muscle, in which O2- production is notoriously increased [59], NITR-generated NO is being 530 
sequestered into ONOO- production instead of cGMP activation, thus reducing the 531 
proportional NO available to GU signalling.  despite an increased NITR-nitrite-NO pool. 532 
We have assessed various indices of mitochondrial respiratory function in 533 
permeabilised red (RG) and white (WG) gastrocnemius fibre bundles. Permeabilisation of 534 
intact muscle bundles and delivery of optimal substrate concentrations allows for the 535 
measurement of the mitochondrial capacity independent of substrate delivery capacity. 536 
Indeed, even in this optimised environment, we demonstrate a reduced capacity (up to 25% 537 
of CON) to phosphorylate ADP in both WG and RG from the mdx mouse. This is consistent 538 
with others [64, 65] who have reported similar depressions in ADP-stimulated 539 
phosphorylating respiration in mdx skeletal muscle fibres. NITR did not improve 540 
phosphorylating or maximal uncoupled respiration in either CON or mdx skeletal muscle but 541 
did decrease CIV activity in both CON and mdx RG. CIV inhibition is an established effect of 542 
reversible competitive binding of NO to heme-copper sites in lieu of O2 on CIV, in addition to 543 
CI and CIII [66, 67, 68]. Despite the inhibitory effect of NITR on CIV activity and therefore 544 
ETS respiratory capacity, the lack of effect on phosphorylating and maximal uncoupled 545 
respiration was unexpected, since NITR has been previously shown to improve various 546 
mitochondrial properties through stimulation of mitochondrial biogenesis and improved 547 
coupling of O2 consumption to ATP production [37]. Since NO is a highly reactive molecule 548 
that, to exert its biological role, must be produced in close proximity to its effector targets, the 549 
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exogenous NO source afforded by NITR supplementation in our study may not be 550 
penetrating the muscle fibres sufficiently, or in sufficient concentration, to modulate 551 
mitochondrial function.  This is particularly true of the mitochondrial function governed by 552 
nuclear gene regulation such as mitochondrial biogenesis and uncoupling. Aquilano et al. 553 
[69], for instance, have demonstrated that the loss of nNOS-generated NO production 554 
nearby the nucleus is a causative factor of the impairment of mitochondrial biogenesis in 555 
skeletal muscle. Thus, while we have evidence of NITR-derived NO penetrating the 556 
mitochondria to induce regulatory adaptations such as inhibition of CIV activity, overall 557 
respiratory capacity which is dictated predominantly by mitochondrial density and coupling is 558 
seemingly unaffected, even in CON mice. This is likely due to the chronic supplementation 559 
period and particular dosage employed in our study. For example, similar to our study, Hezel 560 
et al. [70] did not observe any changes in mitochondrial parameters following 17 months of 561 
NITR supplementation in healthy mice. In contrast, others have shown beneficial 562 
mitochondrial modulation following much shorter supplementation periods [37, 71]. Ashmore 563 
et al. [38] have recently demonstrated that NITR dosage is also important to the control of 564 
the nuclear signalling of mitochondrial biogenesis in which low (0.35mM), medium (0.7mM) 565 
and high (1.4mM) dose NITR therapy (for 15-18 days) in rats had differential effects on  566 
PPARα/β/δ signalling, PGC-1α expression, citrate synthase activity  and mitochondrial fatty 567 
acid oxidation. These data highlight that the promotion of mitochondrial biogenesis might be 568 
an acute, dose-specific response to shorter-term increases in skeletal muscle NO signalling 569 
which may switch off or become desensitised in response to more chronic, prolonged 570 
increases in NO production.   571 
The reduced capacity for mdx skeletal muscle to phosphorylate ADP and to ramp up 572 
respiration during times of metabolic stress may be reflective of uncoupled respiration. In our 573 
study, state 4 respiration was significantly less in both WG and RG of mdx mice and the 574 
RCR was was lower in mdx RG respiring on CI+II substrates highlighting that respiratory 575 
control is compromised in the muscle that is most dependent upon mitochondrial oxidative 576 
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ATP production (i.e. red oxidative muscle). When considered in context of a depressed state 577 
3 and 4 respiration, tighter respiratory control would be required to maintain the ΔΨ and 578 
drive for ATP synthesis, especially given the heightened energy requirements of dystrophic 579 
muscle. Indeed, our observations of a depolarised ΔΨ in isolated mdx mitochondria (C.A. 580 
Timpani, A. Hayes and E. Rybalka, unpublished observations) indicate insufficient coupling 581 
to maintain the drive for ATP synthesis in red muscle at least. Intriguingly, NITR decreased 582 
the RCR only in mdx muscles, indicative of mitochondrial uncoupling.  Uncoupling may be a 583 
beneficial adaptation to ETS dysfunction, to prevent potential hyperpolarisation of the ΔΨ 584 
which is an initiator of mitochondria-mediated apoptosis [72]. Certainly, the role of NITR-585 
derived NO in the regulation of mitochondrial coupling efficiency is unclear since some 586 
studies have demonstrated an enhanced coupling efficiency of human skeletal muscle [37] 587 
while others have shown a reduced coupling efficiency of rodent skeletal muscle [38]. 588 
Despite the obvious species differences between these studies, these data highlight that 589 
NITR-derived NO has a modulatory role on the expression of uncoupling protein 3 (through 590 
increased PPAR-α activation [38]) and adenine nucleotide translocase expression, and 591 
seemingly regulates the leakiness of several respiratory complexes – all of which contribute 592 
to the coupled state of skeletal muscle mitochondria. However, this role requires further 593 
elucidation.  594 
A reduced mitochondrial pool (particularly viable mitochondria) could also explain the 595 
decreased OXPHOS capacity of dystrophic skeletal muscle in our study.  We saw no 596 
genotype or muscle-specific differences in CS activity (a marker of mitochondrial density)  in 597 
our study, however we did see differential expression of ETC complex proteins in mdx RG 598 
and WG whereby complex proteins generally decreased in RG but increased in WG. This 599 
suggests a reduced respiratory capacity despite increased/unchanged mitochondrial density 600 
in mdx RG in particular. We [23] and others [22, 64, 73] have previously reported  this, 601 
highlighting that a reduced mitochondrial functional and/or physical density does not account 602 
for the decreased mitochondrial respiration associated with dystrophin-deficiency but rather, 603 
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that the mitochondrial pool is intrinsically defective. While NITR had no effect on complex 604 
expression in RG from either strain, most complexes (except CIV), were upregulated in 605 
NITR-supplemented CON but not NITR-supplemented mdx WG. In fact, the only observed 606 
effect of NITR in WG that was consistent across strains was an increased CS activity, and 607 
this was reproducible in the RG from mdx but not CON mice. Our finding is curious since  608 
Ashmore et al. demonstrated that a high (1.4 mM) NITR diet increases CS activity in red 609 
SOL muscle from healthy rats, albeit a low (0.35mM) and medium (0.7mM) diet did not [38]. 610 
In context, we supplemented our mice with 1mM NITR. Our data thus suggests that there 611 
are variations in the response of different fibre types to NITR-derived NO dosages, in which 612 
type II fibres are more responsive to a lower NO concentration.  Irrespective, changes in 613 
mitochondrial CS activity and ETC complex expression induced by NITR did not translate to 614 
improved mitochondrial respiration in either CON or mdx muscles in our study.  615 
We found in various respiratory states that NITR reduced H2O2 production in mdx but 616 
not CON skeletal muscle. This would immediately seem to be beneficial, as ROS production 617 
is elevated in dystrophic muscle [59] and NO reduces oxidative stress at the level of the ETS 618 
[74]. However, excessive NO can lead to the generation of RNS in the presence of O2-. In 619 
addition to the inhibition of CIV, NO inhibits electron transfer at CI and CIII of the ETS [75], 620 
producing O2- anions that interact with NO to produce ONOO- which can induce cellular 621 
damage [76]. In our study, we have demonstrated elevated nitrotyrosine content in mdx TA 622 
muscles, which is consistent with increased ONOO- production, and this was dramatically 623 
exacerbated by NITR (2775% increase). Nitrotyrosine labelling corresponded with an 624 
increased area of damage in NITR-supplemented mdx TA sections. In previous studies, NO 625 
donor therapy has been shown to reduce the area of damage in dystrophic muscle, but as 626 
NO donors are typically given in combination with anti-inflammatories [29, 33], our data 627 
suggests that the anti-inflammatory component of these co-compounds is perhaps the more 628 
pertinent effector. NITR also increased the proportion of centronucleated fibres in mdx 629 
muscles, which has been previously observed with NO donors [29, 30] and is reflective of an 630 
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enhanced regenerative capacity in response to NITR-induced damage. NO is a known 631 
stimulator of satellite cell proliferation, which is crucial to skeletal muscle regeneration 632 
following damage [77] and is notably defective in dystrophin-deficient muscle [78, 79]. Since 633 
dystrophic muscle is in a state of enhanced oxidative stress superfluous NITR-derived NO 634 
bioavailability appears detrimental to dystrophic muscle by promoting excess ONOO- 635 
formation which, in turn, may exceed antioxidant buffering capacity to promote muscle 636 
damage and escalate pathology. This effect may be more evident in predominantly white 637 
fast-twitch glycolytic muscles (such as TA) due to the lower endogenous antioxidant content 638 
and therefore NO handling capacity, however further investigation is required to elucidate if 639 
this is true. It is also possible that the absence of  nNOS protein expression, its 640 
translocational capacity to deliver NO to specific intracellular sites and the metabolic 641 
modulatory effects it exerts, may account for the deleterious effect that NITR had on 642 
dystrophic muscle histopathology in our study, since breeding transgenic overexpressing 643 
nNOS mice with the mdx strain results in significant improvements to dystrophic muscle 644 
architecture [26, 27]. NITR therapy, however, might be beneficial for the stimulation of 645 
satellite cell replication and dystrophic skeletal muscle regeneration as we observed 646 
elevated presence of DAPI-positive nuclei in NITR-treated mdx TA. While we did not stain 647 
for Pax-7 (a satellite cell marker), we did label CD45+ immune cell infiltrate and IgG 648 
deposition within the muscle cross-sections – neither of these measures were affected by 649 
NITR SUPP suggesting that the NITR-dependent increase in nuclei content is most likely 650 
reflective of an enhanced satellite cell pool. Therefore NITR therapy could be beneficial 651 
especially if mitochondrial O2- production could be pharmacologically attenuated and RNS-652 
induced damage prevented (such as with antioxidant therapy).  653 
 In summary, our study is the first to demonstrate that an 8 week supplementation 654 
regimen of NITR in drinking water cannot overcome the metabolic dysfunction observed in 655 
the mdx mouse model of DMD. We are the first to examine contraction-induced GU in the 656 
mdx model and to demonstrate that NITR supplementation reduces otherwise normal GU in 657 
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mdx muscles and cannot positively modulate mitochondrial function. Although NITR 658 
supplementation reduced mitochondrial H2O2 emission, it induced mitochondrial uncoupling 659 
in RG, increased muscle fibre nitrosylation (and therefore ONOO- radicals) and promoted 660 
skeletal muscle damage. Our data is consistent with recent literature linking NO to muscle 661 
soreness [80]Together this suggests that enhancing endogenous NO production via 662 
exogenous NITR therapy is contraindicative for the treatment of DMD. This is potentially due 663 
to the fact that there is no concomitant increase in nNOS protein expression and its 664 
regulatory role over metabolic flux control, and, that excessive ROS promotes RNS 665 
production which actually reduced NO bioavailability.  666 
There were some limitations to our study that are worthy of mention. In the first 667 
instance, we did not quantify cGMP levels in EDL and SOL muscles, and thus cannot 668 
confirm that in the presence of heightened O2- production, NO is diverted away from 669 
intracellular signalling pathways (i.e. cGMP production, nucleus signalling of mitochondrial 670 
biogenesis) and into RNS formation. This was because whole EDL and SOL was required  671 
for our primary measure being radioactive GU, and that our other tissues were not 672 
immediately snap frozen, thus cGMP was heavily degraded beyond detectable levels.  673 
Secondly, while simultaneous measurement of O2 flux and H2O2 emission has previously 674 
been well characterised and reported [51, 52, 53], a potential limitation of this assay is that 675 
the supra-physiological chamber pO2 used to overcome O2 diffusion limitations of 676 
permeabilized muscle fibre preparations, may lead to non-physiological rates of H2O2 677 
emission [81]. Therefore, it should be acknowledged that the H2O2 measured using the 678 
present assay may not completely recapitulate in vivo mitochondrial ROS emission rates.  679 
Our data is in stark contrast to previous findings of significant improvements in the 680 
dystrophic condition following NO donor therapy, and in Becker patients following nitrite 681 
supplementation, suggesting that long-term NITR/NO supplementation requires better 682 
characterisation, particularly in conditions of heightened oxidative and/or metabolic stress 683 
such as in DMD. While the precise myopathological mechanisms of NITR has not been fully 684 
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elucidated in the present study, our data is of particular importance considering NITR 685 
therapy is currently in clinical trials for the treatment of DMD patients. 686 

















  704 
28 
 
Table 1. Weights of EDL and SOL used in GU experimentation. 705 
 Left EDL (mg) Right EDL (mg) Left SOL (mg) Right SOL 
(mg) 
CON UNSUPP 12.3 ± 0.8 12.4 ± 1.2 9.0 ± 0.9 9.8 ± 0.9 
CON NITR 11.3 ± 0.3 12.6 ± 0.8 10.3 ± 0.5 10.3 ± 0.6 
mdx UNSUPP 14.8 ± 0.8#### 15.5 ± 1.4#### 13.5 ± 1.3#### 14.9 ± 1.4#### 
mdx NITR 14.7 ± 0.9#### 16.0 ± 0.8#### 13.7 ± 0.8#### 13.3 ± 0.6#### 
 706 
Irrespective of supplementation, both EDL and SOL weight were significantly higher in mdx 707 
mice compared to CON mice. There was no effect of NITR. #### Significant difference from 708 
CON mice p<0.0001. CON UNSUPP n=14; CON NITR n=16; mdx UNSUPP n=12; mdx 709 
NITR n=13. 710 
 711 
Table 2. Weights of the left gastrocnemius used in mitochondrial respiration 712 
experimentation, determination of CS activity and western blotting of mitochondrial 713 




CON UNSUPP 145.18 ± 4.4 46.9 ± 1.7 
CON NITR 145.2 ± 3.3 46.5 ± 1.5 
mdx UNSUPP 169.9 ± 4.2#### 68.9 ± 2.1#### 
mdx NITR 170.2 ± 4.5#### 66.9 ± 4.3#### 
 715 
Irrespective of supplementation, gastrocnemius was significantly higher in mdx mice 716 
compared to CON mice. There was no effect of NITR. Similarly, TA was significantly higher 717 
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in mdx mice compared to CON mice with no effect of NITR observed in either strain. #### 718 
Significant difference from CON mice p<0.0001. CON UNSUPP n=13; CON NITR n=16; 719 
mdx UNSUPP n=12; mdx NITR n=13. 720 
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uptake; mdx: muscular dystrophy x-linked on c57BL/10 background (mouse); H2O2: 726 
hydrogen peroxide; NaNO3: sodium nitrate; NITR: nitrate; nNOS: neuronal nitric oxide 727 
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phosphofructokinase; PGC1-α: PPARγ-coactivator 1α; PKG: cGMP-regulated protein 729 
kinase; PPAR: peroxisome proliferator-activated receptor; RCR: respiratory control ratio; 730 
RNS: reactive nitrogen species; ROS: reactive oxygen species; SOL: soleus; TA: tibilalis 731 
anterior; TCA: tricarboxylic acid; WG: white gastrocnemius.  732 
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Figure Legends 742 
Fig 1. Body weight and average food and water consumption of unsupplemented and 743 
NITR-supplemented mice over the supplementation period. Changes in body weight are 744 
shown as a percentage of pre-supplementation weight (A). Overall, mdx mice gained more 745 
weight over the 8 week supplementation period compared to CON (p<0.0001, A). NITR had 746 
no effect on mdx weight gain but did increase weight gain in CON compared to CON 747 
UNSUPP (p<0.05). Over the 8 week supplementation period, food (B) and water 748 
consumption (C) did not differ between unsupplemented and supplemented animals 749 
(p>0.05) except for food consumption during week two where CON UNSUPP consumed 750 
more than all groups (p<0.05).  CON UNSUPP n=16; CON NITR n=17; mdx UNSUPP n=14; 751 
mdx NITR n=18.  752 
 753 
Fig 2. GU in isolated EDL and SOL from unsupplemented and NITR supplemented 754 
CON and mdx mice. In all groups,   contraction-induced GU significantly compared to basal 755 
conditions (p<0.05, A). NITR increased contraction-induced GU in CON EDL (p<0.05) but in 756 
contrast, reduced both basal- and contraction-induced GU in mdx EDL (p<0.05). For the 757 
SOL, both basal- and contraction-induced GU (B) were comparable (p>0.05). NITR reduced 758 
basal GU in mdx SOL (p<0.05) but had no effect in CON SOL. CON UNSUPP n=9-13; CON 759 
NITR n=11-; mdx UNSUPP n=11; mdx NITR n=10-12. 760 
 761 
Fig 3. Mitochondrial function in intact, permeabilised muscle fibres from the white and 762 
red portion of gastrocnemius from unsupplemented and NITR-supplemented CON and 763 
mdx mice. State 4 leak respiration (A) is significantly reduced in mdx compared to CON 764 
WG, irrespective of substrate combination (p<0.05). ADP-stimulated state 3 respiration (A) is 765 
significantly reduced in mdx compared to CON WG (p<0.05) with NITR having no effect. 766 
FCCP-stimulated uncoupled respiration (A) is significantly reduced in mdx WG compared 767 
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with CON (p<0.05) with no difference in CIV activity detected between CON and mdx WG 768 
(p>0.05).  The respiratory control ratio (RCR; B), an indicator of the coupling of O2 769 
consumption and ATP production at the ETS, was comparable between CON and mdx WG, 770 
although a trend for mdx to be lower was detected (p=0.083). When respiring on CI+II- 771 
substrates, the RCR was significantly lower across all groups (p<0.0001). State 4 leak 772 
respiration (C) is significantly reduced in mdx compared to CON RG, irrespective of 773 
substrate combination (p<0.01). ADP-stimulated state 3 respiration (C) is significantly 774 
reduced in mdx compared to CON RG (p<0.001) with NITR having no effect on 775 
phosphorylating respiration. FCCP-stimulated uncoupled respiration (C) is significantly 776 
reduced in mdx compared with CON (p<0.001). CIV activity (C) is significantly reduced in 777 
mdx UNSUPP compared to CON UNSUPP (p<0.01) with NITR inducing a significant 778 
decrease in both CON and mdx (p<0.01). The RCR (D) in mdx RG during CI+II-stimulated 779 
respiration is lower compared to CON (p<0.0001) with NITR decreasing the RCR in mdx 780 
during CI+II-stimulated respiration (p<0.001 respectively). CON UNSUPP n=12-13; CON 781 
NITR n=12-13; mdx UNSUPP n=10-11; mdx NITR n=11-12. 782 
 783 
Fig 4. Mitochondrial respiratory chain complex proteins, and citrate synthase activity, 784 
from the white portion of gastrocnemius from unsupplemented and NITR-785 
supplemented CON and mdx mice. In mdx UNSUPP WG, expression of CII (p<0.05; B), 786 
CIII (p<0.01; C), CIV (p<0.05; D) and CV (p<0.01; E) were greater compared to CON 787 
UNSUPP.  NITR induced an increase in CI (p<0.01; A), CII (p<0.01; B), CIII (p<0.05; C) and 788 
CV (p<0.05; E) subunits in CON WG but not in mdx WG. NITR also increased CS activity (F) 789 
in both CON and mdx WG (p<0.05) with a trend for CS activity to be higher in mdx UNSUPP 790 
compared to CON (p=0.07).  Representative western blots of proteins from each of the five 791 
mitochondrial respiratory complexes (G) with coomassie blue stains of the respective 792 




Fig 5. Mitochondrial respiratory chain complex proteins, and citrate synthase activity, 795 
from the red portion of gastrocnemius from unsupplemented and NITR supplemented 796 
CON and mdx mice. Overall, expression of CI, CIII, CIV and CV subunits were decreased 797 
in mdx RG compared to CON (p<0.05; A, C, D, E respectively). NITR increased CS activity 798 
in mdx RG but not in CON (p<0.05; F). Representative western blots of proteins from each 799 
of the five mitochondrial respiratory complexes (G) with coomassie blue stains of the 800 
respective western blots to demonstrate equal loading of the total protein (H). n= 8 per 801 
group.  802 
 803 
Fig 6. H2O2 emission in intact fibres from the white (A) and red (B) portions of 804 
gastrocnemius from unsupplemented and NITR-supplemented CON and mdx mice. In 805 
WG, NITR induced a decreased H2O2 emission during state 4 leak respiration (A) in CON 806 
during CI-stimulated respiration and in both CON and mdx during CI+II-stimulated 807 
respiration (p<0.05). In WG, no significant difference was detected in H2O2 emission during 808 
ADP-stimulated state 3 respiration (A). There was no significant difference in H2O2 emission 809 
during FCCP-stimulated uncoupled respiration (A) in WG. In RG (B), NITR induced a 810 
decrease in H2O2 emission during state 4 leak respiration in mdx muscle during CI+II-811 
stimulated respiration (p<0.001). In mdx RG (B), H2O2 emission during ADP-stimulated state 812 
3 respiration was significantly less compared to CON WG (p<0.05) with NITR having no 813 
effect (p>0.05). While there was no differences in H2O2 emission during FCCP respiration 814 
between CON UNSUPP and mdx UNSUPP RG (p>0.05, B), NITR reduced  H2O2 emission  815 
in mdx RG compared to mdx UNSUPP (p<0.05). CON UNSUPP n=12-13; CON NITR 816 
n=12-13; mdx UNSUPP n=10-11; mdx NITR n=11-12. 817 
 818 
Fig 7. Immunohistological analysis of TA from unsupplemented and NITR 819 
supplemented CON and mdx mice. Nitrotyrosine expression was higher in mdx TA 820 
compared to CON (p<0.0001, A) with NITR supplementation elevating nitrotyrosine 821 
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expression in both CON (p<0.05) and mdx (p<0.0001). Nuclei content was higher in mdx TA 822 
compared to CON (p<0.0001, B) with NITR further increasing nuclei content in mdx TA 823 
(p<0.0001). CD45 infiltration (C) and IgG staining (D) was elevated in mdx TA compared to 824 
COM (p<0.001 and p<0.01 respectively) and NITR supplementation had no effect in either 825 
CON or mdx TA (p>0.05). Scale bars= 100 µm. CON UNSUPP n=3-4; CON NITR n=3-4; 826 
mdx UNSUPP n=3-4; mdx NITR n=3-4. 827 
 828 
Fig 8. Histological analysis of TA from unsupplemented and NITR supplemented CON 829 
and mdx mice. The frequency histogram (A) indicates an increase in fibre size of mdx TA 830 
with fibres more frequent from 6000-12000 µm (p<0.0001). NITR had no effect on the 831 
distribution of CON or mdx fibres but there was a trend for an increased number of fibres 832 
around 6000 µm (p=0.068). Mean fibre size (C) was significantly greater in mdx TA (p<0.01) 833 
with a trend for NITR to increase fibre size in mdx TA (p=0.093). Damaged area (D) and 834 
percentage of centronucleated fibres (E) was significantly higher in mdx TA (p<0.01 and 835 
p<0.0001 respectively) with NITR stimulating further damage and regeneration (p<0.01). 836 
CON UNSUPP n=11; CON NITR n=12; mdx UNSUPP n=11; mdx NITR n=10. 837 
 838 
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